pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › BMY

BMY PDUFA Date: iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone

FDA decision (PDUFA) target 2026-08-17 · Bristol-Myers Squibb Company · Relapsed/refractory multiple myeloma (RRMM)

BMY run-up into the PDUFA (last ~120 days)

$62.37$54.46
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-08-17
Drug / candidateiberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone
IndicationRelapsed/refractory multiple myeloma (RRMM)
CompanyBristol-Myers Squibb Company
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT04975997 · active

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the BMY PDUFA date?
The FDA PDUFA target date for BMY (Bristol-Myers Squibb Company) is 2026-08-17 for iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is BMY's drug iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone?
iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone is Bristol-Myers Squibb Company's candidate under FDA review for Relapsed/refractory multiple myeloma (RRMM).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.